#USA #San Diego #Class Action #Robbins LLP #Nektar Therapeutics

Robbins LLP Encourages Nektar Therapeutics Investors to Join Class Action Lawsuit

Robbins LLP is reaching out to investors who incurred losses in Nektar Therapeutics (NASDAQ: NKTR) during the specified class period, which spans from February 26, 2025, to December 15, 2025. A class action lawsuit has been initiated on behalf of all individuals who purchased securities of Nektar during this time. This action has been prompted by serious allegations that the biopharmaceutical company falsely represented the success potential of its clinical trials, particularly the trial concerning rezpegaldesleukin, a candidate treatment for autoimmune disorders.

The Allegations Against Nektar Therapeutics

The crux of the allegations lies in claims that Nektar did not follow necessary protocols during the execution of its REZOLVE-AA trial. According to the lawsuit:

• - The company purportedly failed to properly manage the inclusion of participants, which led to speculation that the trial results would be adversely affected.
• - Nektar's representations about the integrity and potential success of the trial were grossly exaggerated.
• - On December 16, 2025, the company's unexpected announcement regarding the trial's failure to meet statistical significance led to a significant drop in stock price. The share price fell by $4.14, or approximately 7.77%, closing at $49.16.

These developments have aroused concerns among investors who feel they were misled about the company’s future prospects, particularly those who may have acted upon the misleading public statements made by Nektar’s executives. Investors are rightly distressed, as the announcement highlighted fundamental issues with the conducted trial that the company had previously downplayed.

What Investors Should Do

Investors who experienced financial loss due to their involvement with Nektar Therapeutics now have an opportunity to potentially recover those losses. By participating in this class action, they can help hold the company accountable for its actions. If individuals wish to become part of the lawsuit or serve as lead plaintiffs, Robbins LLP encourages them to reach out for more information.

Steps for Participation

1. Contact Robbins LLP: Interested parties can fill out a submission form, email attorney Aaron Dumas, Jr., or call the firm directly at (800) 350-6003 for guidance and further details on the process.
2. Understanding the Lead Plaintiff Role: The lead plaintiff acts on behalf of other investors in the lawsuit. While participation is essential to serve in this role, it is not mandatory for those seeking recovery from the lawsuit. Investors can choose to remain as absent class members if they prefer.
3. Contingency Fee Basis: Importantly, all representation from Robbins LLP is on a contingency fee basis; shareholders will not incur any upfront fees or expenses for representation.

About Robbins LLP

Robbins LLP is an esteemed firm specializing in shareholder rights litigation. Since its inception in 2002, it has remained steadfast in its commitment to aiding shareholders in recovering losses, enhancing corporate governance, and holding executives accountable for their misconduct. The firm has developed a reputation for rigorous legal advocacy and strives to assist investors in navigating the complexities of stockholder rights issues.

For ongoing updates and alerts regarding any settlements in the Nektar Therapeutics case or other corporate misconduct, interested individuals may consider signing up for Stock Watch, a free service provided by Robbins LLP.

Take action now to safeguard your rights as an investor. Contact Robbins LLP today if you believe you might be eligible for participation in this pivotal class action lawsuit against Nektar Therapeutics. Your chance to advocate for accountability and recovery starts here.